GlucoTrack (GCTK) 10-Q 14 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 10, 2020
Cover [Abstract]
Entity Registrant Name	Integrity Applications, Inc.
Entity Central Index Key	0001506983
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity's Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		200,525,066
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 11,512,666	$ 418,621
Accounts receivable, net	69,978	70,161
Inventory	252,937	184,602
Other current assets	81,004	44,658
Total current assets	11,916,585	718,042
Operating lease right-of-use assets, net	115,072	187,232
Property and equipment, net	124,838	133,795
Long-Term Restricted Cash	56,911	57,092
TOTAL ASSETS	12,213,406	1,096,161
Current Liabilities
Accounts payable	1,166,098	1,534,078
Operating lease liabilities, current	85,450	142,090
Other current liabilities	321,627	596,087
Total Current Liabilities	1,573,175	2,272,255
Long Term Liabilities
Long-Term Loans from Stockholders	188,255	190,365
Operating lease liabilities, non-current	29,622	45,143
Total long-term liabilities	217,877	235,508
Total Liabilities	1,791,052	2,507,763
Stockholders' Equity (Deficit)
Common Stock of $ 0.001 par value ("Common Stock"): 500,000,000 shares authorized; 200,525,066 and 161,858,436 shares issued and outstanding as of June 31, 2020 and December 31, 2019, respectively	200,525	161,858
Additional paid-in capital	102,052,553	89,005,407
Receipts on account of shares	62,086
Accumulated other comprehensive income	118,061	124,062
Accumulated deficit	(92,010,871)	(90,702,929)
Total Stockholders' equity (deficit)	10,422,354	(1,411,602)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 12,213,406	$ 1,096,161

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	200,000,000
Common stock, shares issued	200,525,066	161,858,436
Common stock, shares outstanding	200,525,066	161,858,436

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue	$ 97	$ 110,518	$ 2,271	$ 136,080
Research and development	378,892	401,122	793,931	826,239
Selling and marketing expenses	90,061	150,953	180,817	276,296
General and administrative	142,329	452,749	394,198	952,904
Total operating expenses	611,282	1,004,824	1,368,946	2,055,439
Operating Loss	(611,185)	(894,306)	(1,366,675)	(1,919,359)
Finance Income (expense), net:	37,012	(4,551)	58,733	(1,151)
Net Loss	(574,173)	(898,857)	(1,307,942)	(1,920,510)
Other comprehensive income (expenses):
Foreign currency translation adjustment	(25,292)	6,510	(6,001)	(26,638)
Comprehensive loss for the period	$ (599,465)	$ (892,347)	$ (1,313,943)	$ (1,947,148)
Net Loss per Common Share
Basic	$ 0	$ (0.01)	$ (0.01)	$ (0.01)
Diluted	$ 0	$ (0.01)	$ (0.01)	$ (0.01)
Average number of common shares used in computing basic and diluted loss per share	200,525,066	149,776,875	191,166,219	147,256,546

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Receipt on Account of Shares [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 141,638	$ 84,007,612		$ 164,232	$ (87,186,783)	$ (2,873,301)
Balance, shares at Dec. 31, 2018	141,634,700
Loss for the period					(1,920,510)	(1,920,510)
Other comprehensive income (loss)				(26,638)		(26,638)
Amounts allocated to Series D-1, D-2 and Series D-3 Warrants, net		31,915				31,915
Amount allocated to issuance of Common Stock from Series D offering	$ 18,892	3,898,155				3,917,047
Amount allocated to issuance of Common Stock from Series D offering, shares	18,889,618
Issuance of shares as settlement of financial liabilities	$ 1,190	305,866				307,056
Issuance of shares as settlement of financial liabilities, shares	1,190,141
Warrants issued as consideration for placement agent services		249,612				249,612
Stock-based compensation	$ 235	329,935				330,170
Stock-based compensation, shares	232,560
Balance at Jun. 30, 2019	$ 161,955	88,823,095		137,594	(89,107,293)	15,351
Balance, shares at Jun. 30, 2019	161,947,019
Balance at Mar. 31, 2019	$ 146,447	85,244,557		131,084	(88,208,436)	(2,686,348)
Balance, shares at Mar. 31, 2019	146,440,814
Loss for the period					(898,857)	(898,857)
Other comprehensive income (loss)				6,510		6,510
Amounts allocated to Series D-1, D-2 and Series D-3 Warrants, net		26,287				26,287
Amount allocated to issuance of Common Stock from Series D offering	$ 15,392	3,197,418				3,212,810
Amount allocated to issuance of Common Stock from Series D offering, shares	15,389,925
Warrants issued as consideration for placement agent services		203,366				203,366
Stock-based compensation	$ 116	151,467				151,583
Stock-based compensation, shares	116,280
Balance at Jun. 30, 2019	$ 161,955	88,823,095		137,594	(89,107,293)	15,351
Balance, shares at Jun. 30, 2019	161,947,019
Balance at Dec. 31, 2019	$ 161,858	89,005,407		124,062	(90,702,928)	(1,411,602)
Balance, shares at Dec. 31, 2019	161,858,436
Loss for the period					(1,307,942)	(1,307,942)
Other comprehensive income (loss)				(6,001)		(6,001)
Amount allocated to issuance of Common Stock from Series D offering	$ 37,500	12,215,682				12,253,182
Amount allocated to issuance of Common Stock from Series D offering, shares	37,500,000
Issuance of shares as settlement of financial liabilities	$ 1,167	62,126	62,086			125,379
Issuance of shares as settlement of financial liabilities, shares	1,166,630
Warrants issued as consideration for placement agent services		756,087				756,087
Stock-based compensation		13,251				13,251
Stock-based compensation, shares
Balance at Jun. 30, 2020	$ 200,525	102,052,553	62,086	118,061	(92,010,871)	10,422,354
Balance, shares at Jun. 30, 2020	200,525,066
Balance at Mar. 31, 2020	$ 199,358	101,978,019	63,293	143,353	(91,436,698)	10,947,325
Balance, shares at Mar. 31, 2020	199,358,436
Loss for the period					(574,173)	(574,173)
Other comprehensive income (loss)				(25,292)		(25,292)
Issuance of shares as settlement of financial liabilities	$ 1,167	(62,126)	(1,207)			62,086
Issuance of shares as settlement of financial liabilities, shares	1,166,630
Stock-based compensation		12,408				12,408
Stock-based compensation, shares
Balance at Jun. 30, 2020	$ 200,525	$ 102,052,553	$ 62,086	$ 118,061	$ (92,010,871)	$ 10,422,354
Balance, shares at Jun. 30, 2020	200,525,066

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Change in Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Loss for the period	$ (1,307,942)	$ (1,920,510)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	23,265	26,252
Stock-based compensation	13,251	330,170
Linkage difference on principal of loans from stockholders	(1,506)	3,865
Changes in assets and liabilities:
Decrease (increase) in accounts receivable	(40)	1,184
Decrease (increase) in inventory	(68,920)	49,228
Decrease (Increase) in other current assets	(36,451)	(52,194)
Operating lease right-of-use assets		51,787
Increase (decrease) in accounts payable	(365,843)	(481,558)
Increase (decrease) in other current liabilities	(147,817)	2,520
Operating lease liabilities		(51,787)
Net cash used in operating activities	(1,892,003)	(2,041,043)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(14,842)	(9,913)
Net cash used in investing activities	(14,842)	(9,913)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock, net of cash issuance expenses	13,009,269	4,165,079
Proceeds allocated to Series D Warrants, net of cash issuance expenses		33,495
Net cash provided by financing activities	13,009,269	4,198,574
Effect of exchange rate changes on cash and cash equivalents, and restricted cash	(8,560)	34,281
Increase (decrease) in cash, cash equivalents, and restricted cash	11,093,864	2,181,899
Cash, cash equivalents, and restricted cash at beginning of the period	475,713	149,684
Cash, cash equivalents, and restricted cash, end of period	$ 11,569,577	$ 2,331,583

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Change in Cash Flows (Unaudited) (Parenthetical)	6 Months Ended
	Jun. 30, 2020USD ($)
Fair value of warrants issued as consideration for placement agent services	$ 756,087
Independent Board Members [Member]
Payment of management fee	$ 63,000

General

General	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	NOTE 1 – GENERAL A. Integrity Applications, Inc. (the “Company”) was incorporated on May 18, 2010 under the laws of the State of Delaware. On July 15, 2010, Integrity Acquisition Corp. Ltd. (hereinafter: “Integrity Acquisition”), a wholly owned Israeli subsidiary of the Company, which was established on May 23, 2010, completed a merger with A.D. Integrity Applications Ltd. (hereinafter: “Integrity Israel”), an Israeli corporation that was previously held by the stockholders of the Company. Pursuant to the merger, all equity holders of Integrity Israel received the same proportional ownership in the Company as they had in Integrity Israel prior to the merger. Following the merger, Integrity Israel became a wholly-owned subsidiary of the Company. As the merger transaction constituted a structural reorganization, the merger has been accounted for at historical cost in a manner similar to a pooling of interests. Integrity Israel was incorporated in 2001 and commenced its operations in 2002. Integrity Israel, a medical device company, focuses on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and prediabetes. B. Since its incorporation, the Company’s material operations have all been carried out by Integrity Israel. The development and commercialization of Integrity Israel’s product is expected to require substantial expenditures. The Company has not yet generated significant revenues from operations, and therefore they are dependent upon external sources for financing their operations. As of June 30, 2020, the Company has an accumulated deficit of $92,010,871. In addition, in each year since its inception, the Company reported losses from operations and negative cash flows from operating activities As described in Note 3, on February 14, 2020, the Company closed on a $15 million private placement of its common stock, for which it received net cash in excess of $13,009,269. As of June 30, 2020 the company has cash, cash equivalents and restricted cash in the amount of $11,569,577, which is expected to be sufficient to meet its capital needs for at least 12 months from the date of issuance of these financial statements, thus the Company is expected to be able to operate as a going concern for at least 12 months from the date hereof.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A. Basis of presentation Accounting Principles The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with our consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Securities and Exchange Commission (“SEC”) on April 14, 2020. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature The results for the six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other interim period or for any future period. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation. Net (Loss) Per Share The Company computes net loss per share in accordance with ASC 260, “Earnings per share”. Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, net of the weighted average number of treasury shares (if any). Diluted loss per common share is computed similar to basic loss per share, except that the denominator is increased to include the number of additional potential shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. Potential shares of common stock are excluded from the computation for a period in which a net loss is reported or if their effect is anti-dilutive. An amount of 81,672,122 and 77,558,958 weighted average outstanding stock options and stock warrants have been excluded from the calculation of the diluted net loss per share for the period of six months ended June 30, 2020 and 2019, respectively, because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was determined to be anti-dilutive. B. Use of estimates in the preparation of financial statements The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determination of net realizable value of inventory. C. Reclassified Amounts Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications did not have material effect on the reported results of operations, shareholder’s equity or cash flows .

Recent Events

Recent Events	6 Months Ended
	Jun. 30, 2020
Recent Events
Recent Events	NOTE 3 – RECENT EVENTS A. On January 21, 2020, the Company announced that it has received CE Mark approval for a major enhancement to GlucoTrack, allowing for a user to perform the calibration process by themselves, without the need for a certified calibrator. The initial CE Mark approval received for GlucoTrack required a calibration process that took three hours to complete, required eight invasive finger stick reference measurements, needed to be repeated every thirty days and required a certified calibrator to perform the calibration. After a series of successful enhancements and approvals, the calibration process now takes just thirty minutes, requires just three invasive reference measurements, and needs to be repeated only once every six months. With self-calibration, a user can now perform this simplified process in the privacy and convenience of their own home. B. On February 14, 2020, the Company entered into a Securities Purchase Agreement and Registration Rights Agreement (collectively, the “Agreements”) with an accredited investor, pursuant to which the accredited investor purchased 37,500,000 shares of the Company’s common stock, par value $0.001 per share, for an aggregate gross purchase price of $15,000,000. The Company received net proceeds of $13,009,269 after payment of fees to its placement agent and legal and accounting fees. In connection with the agreement, our placement agent was paid $1,950,000 in fees in connection therewith, and issued five years warrant to purchase 3,750,000 shares at an exercise price per share of $0.40 with terms similar to the terms of the Placement Agent Warrants issued in 2019. The fair value of the warrants as of the agreement date was $756,087. C. The Company may be at risk as a result of the current COVID-19 pandemic. Risks that could affect its business include the duration and scope of the COVID-19 pandemic and the impact on the demand for its products; actions by governments, businesses and individuals taken in response to the pandemic; the length of time of the COVID-19 pandemic and the possibility of its reoccurrence; the timing required to develop effective treatments and a vaccine in the event of future outbreaks; the eventual impact of the pandemic and actions taken in response to the pandemic on global and regional economies; and the pace of recovery when the COVID-19 pandemic subsides.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventories	NOTE 4 – INVENTORIES US dollars June 30, December 31, 2020 2019 (unaudited) Raw materials 27,956 18,381 Work in process 1,630,296 1,541,932 Finished products 51,282 80,886 1,709,534 1,641,199 Less – provision for slow moving inventory (1,456,597 ) (1,456,597 )

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	NOTE 5 – LEASES We have entered into several non-cancellable operating lease agreements for our offices and three vehicles. Our leases have original lease periods expiring between 2020 and 2022. Payments due under such lease contracts include primarily fix payments. We do not assume renewals in our determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. The components of lease costs, lease term and discount rate are as follows: US dollars Six Months Ended June 30, 2020 (unaudited) Operating lease cost: Office space 60,000 Vehicles 19,332 79,332 Remaining Lease Term Office space 0.42 years Vehicles 1.89 years Weighted Average Discount Rate Office space 10 % Vehicles 10 % The following is a schedule, by years, of maturities of operating lease liabilities as of June 30, 2020: US dollars June 30, 2020 (unaudited) Period: The remainder of 2020 69,470 2021 34,254 2022 18,766 Total operating lease payments 122,490 Less: imputed interest 7,418 Present value of lease liabilities 115,072

Financing Income (Expenses), Ne

Financing Income (Expenses), Net	6 Months Ended
	Jun. 30, 2020
Other Income and Expenses [Abstract]
Financing Income (Expenses), Net	NOTE 6 – FINANCING INCOME (EXPENSES), NET US dollars US dollars Six-month period ended June 30, Three-month period ended June 30, 2020 2019 2020 2019 (Unaudited) (Unaudited) Israeli CPI linkage difference on principal of loans from stockholders 1,506 (3,865 ) 1,692 (3,342 ) Exchange rate differences (6,519 ) 10,569 (6,398 ) 2,506 Interest (Income) expenses on credit from banks and other 63,746 (7,855 ) 41,718 (3,715 ) 58,733 (1,151 ) 37,012 (4,551 )

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 7 – SUBSEQUENT EVENTS None.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	A. Basis of presentation Accounting Principles The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with our consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Securities and Exchange Commission (“SEC”) on April 14, 2020. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature The results for the six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other interim period or for any future period. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation. Net (Loss) Per Share The Company computes net loss per share in accordance with ASC 260, “Earnings per share”. Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, net of the weighted average number of treasury shares (if any). Diluted loss per common share is computed similar to basic loss per share, except that the denominator is increased to include the number of additional potential shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. Potential shares of common stock are excluded from the computation for a period in which a net loss is reported or if their effect is anti-dilutive. An amount of 81,672,122 and 77,558,958 weighted average outstanding stock options and stock warrants have been excluded from the calculation of the diluted net loss per share for the period of six months ended June 30, 2020 and 2019, respectively, because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was determined to be anti-dilutive.
Use of Estimates in the Preparation of Financial Statements	B. Use of estimates in the preparation of financial statements The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determination of net realizable value of inventory.
Reclassified Amounts	C. Reclassified Amounts Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications did not have material effect on the reported results of operations, shareholder’s equity or cash flows .

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories	US dollars June 30, December 31, 2020 2019 (unaudited) Raw materials 27,956 18,381 Work in process 1,630,296 1,541,932 Finished products 51,282 80,886 1,709,534 1,641,199 Less – provision for slow moving inventory (1,456,597 ) (1,456,597 ) 252,937 184,602

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of Lease Costs, Lease Term and Discount	The components of lease costs, lease term and discount rate are as follows: US dollars Six Months Ended June 30, 2020 (unaudited) Operating lease cost: Office space 60,000 Vehicles 19,332 79,332 Remaining Lease Term Office space 0.42 years Vehicles 1.89 years Weighted Average Discount Rate Office space 10 % Vehicles 10 %
Schedule of Operating Lease Maturity Payments	The following is a schedule, by years, of maturities of operating lease liabilities as of June 30, 2020: US dollars June 30, 2020 (unaudited) Period: The remainder of 2020 69,470 2021 34,254 2022 18,766 Total operating lease payments 122,490 Less: imputed interest 7,418 Present value of lease liabilities 115,072

Financing Income (Expenses), _2

Financing Income (Expenses), Net (Tables)	6 Months Ended
	Jun. 30, 2020
Other Income and Expenses [Abstract]
Schedule of Financing Income (Expenses), Net	US dollars US dollars Six-month period ended June 30, Three-month period ended June 30, 2020 2019 2020 2019 (Unaudited) (Unaudited) Israeli CPI linkage difference on principal of loans from stockholders 1,506 (3,865 ) 1,692 (3,342 ) Exchange rate differences (6,519 ) 10,569 (6,398 ) 2,506 Interest (Income) expenses on credit from banks and other 63,746 (7,855 ) 41,718 (3,715 ) 58,733 (1,151 ) 37,012 (4,551 )

General (Details Narrative)

General (Details Narrative) - USD ($)	Feb. 14, 2020	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit		$ (92,010,871)	$ (90,702,929)
Proceeds from issuance of private placement	$ 15,000,000
Excess of cash received, net	$ 13,009,269
Cash, cash equivalents and restricted cash i		$ 11,569,577	$ 475,713	$ 2,331,583	$ 149,684

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Accounting Policies [Abstract]
Diluted net loss per share	81,672,122	77,558,958

Recent Events (Details Narrativ

Recent Events (Details Narrative) - USD ($)	Feb. 14, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Common stock par value			$ 0.001		$ 0.001
Number of common stock issued, value		$ 3,212,810	$ 12,253,182	$ 3,917,047
Proceeds from private placement	$ 15,000,000
Securities Purchase Agreement and Registration Rights Agreement [Member] | Accredited Investor [Member]
Number of common stock issued	37,500,000
Common stock par value	$ 0.001
Number of common stock issued, value	$ 15,000,000
Securities Purchase Agreement and Registration Rights Agreement [Member] | Placement Agent [Member]
Proceeds from private placement	$ 13,009,269
Placement agent fees
Warrant term					5 years
Warrant to purchase of common stock					3,750,000
Warrant exercise price per share					$ 0.40
Fair value of warrant

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 27,956	$ 18,381
Work in process	1,630,296	1,541,932
Finished products	51,282	80,886
Total	1,709,534	1,641,199
Less - provision for slow moving inventory	(1,456,597)	(1,456,597)
Inventory, net	$ 252,937	$ 184,602

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Costs, Lease Term and Discount (Details)	6 Months Ended
	Jun. 30, 2020USD ($)
Operating lease cost	$ 79,332
Office Space [Member]
Operating lease cost	$ 60,000
Remaining Lease Term	5 months 1 day
Weighted Average Discount Rate	10.00%
Vehicles [Member]
Operating lease cost	$ 19,332
Remaining Lease Term	1 year 10 months 21 days
Weighted Average Discount Rate	10.00%

Leases - Schedule of Operating

Leases - Schedule of Operating Lease Maturity Payments (Details)	Jun. 30, 2020USD ($)
Leases [Abstract]
The remainder of 2020	$ 69,470
2021	34,254
2022	18,766
Total operating lease payments	122,490
Less: imputed interest	7,418
Present value of lease liabilities	$ 115,072

Financing Income (Expenses), _3

Financing Income (Expenses), Net - Schedule of Financing Income (Expenses), Net (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Other Income and Expenses [Abstract]
Israeli CPI linkage difference on principal of loans from stockholders	$ 1,673	$ (3,342)	$ 1,506	$ (3,865)
Exchange rate differences	(6,398)	2,506	(6,519)	10,569
Interest Income (expenses) on credit from banks and others	41,718	(3,715)	63,766	(7,855)
Financing (income) expenses, net	$ 37,012	$ (4,551)	$ 58,733	$ (1,151)